European drug authorities have issued recommendations to address ongoing shortages in glucagon-like peptide 1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity. These drugs include Ozempic (semaglutide), Saxenda (liraglutide), Trulicity (dulaglutide), and Victoza (liraglutide). Since 2022, GLP-1 receptor agonists have gained popularity on social media…
